Leadership Team

---

Chief Executive Officer, Co-Founder & Board Member

 Alex served previously as Evergreen Theragnostics' CFO, overseeing the finance function and CDMO business operations, and aided the $1B+ sale to Lantheus Holdings in 2025 (NASDAQ: LNTH). Previously he was the VP, Controller, and Interim-CFO at Blue Foundry Bancorp, a $2B bank, leading the accounting function in their 2021 IPO raising $277MM (NASDAQ: BLFY). He began his career in the audit practice at KPMG. 

Chief Operating Officer, Co-Founder & Board Member

 Dr. Nandi is a seasoned pharmaceutical professional with nearly 25 years of experience, supporting and executing strategic operational initiatives to drive business growth. He is skilled in CMC, IP, portfolio & program management, with a specialization in regulatory filing, manufacturing, and new product launches.  Previously, he was the Chief Scientific Officer at Jubilant Radiopharma. Prior roles include CSO at Vertice Pharma, VP of R&D at Impax Laboratories, and over a decade at Sandoz / Novartis. He holds a PhD from St. John's University and an MBA from Rutgers. 

Director of Manufacturing, Co-Founder

Kyle has extensive experience in radiopharmaceutical manufacturing, nuclear pharmacy operations, and clinical pharmacy. Prior roles include VP of Manufacturing, Site Head, and Radiation Safety Officer at Evergreen Theragnostics, Facility Manager and Radiopharmacist at SOFIE, and Pharmacy Manager at CVS Health. He holds a Doctor of Pharmacy degree from MCPHS University and a Masters in Radiation Health Physics from Oregon State University.

Advisor, Co-Founder, Board Member

Dr. Lyashchenko is a faculty member of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. He oversees the Radiochemistry and Molecular Imaging Probe Core at MSKCC and has translated 50+ agents into radio pharmaceutical development . He was a co-founder of Evergreen Theragnostics and serves as an advisor to the IAEA and WHO to enhance global radiopharmaceutical access.  

Advisor, Board Member

Pietro graduated in Pharmacy from the University of Perugia and the School of Pharmacy in London. He began his professional career at Advanced Accelerator Applications, a leading pharmaceutical company in the radiopharmaceutical sector, which then became a Novartis Company in 2018, holding various roles of responsibility and managing different production sites in Italy and America. He currently serves as VP Manufacturing & Operations at BetaGlue Therapeutics, an innovative start-up operating in the field of medical devices.